The U.S. Food and Drug Administration is warning consumers that Reumofan Plus, marketed as a “natural” dietary supplement for pain relief and other serious conditions, contains several active pharmaceutical ingredients not listed on the label that could be harmful.

The U.S. Food and Drug Administration is warning consumers and health care professionals about a counterfeit version of Teva Pharmaceutical Industries’ Adderall 30 milligram tablets that is being purchased on the Internet.

A team of researchers led by the U.S. Food and Drug Administration has discovered a new mechanism for identifying and understanding drug-related autoimmune reactions.

FDA is alerting healthcare providers of a potential safety risk in some Carpuject pre-filled cartridges manufactured by Hospira , Inc.

The U.S. Food and Drug Administration (FDA) has completed its evaluation of a report of a patient who died after the first dose of multiple sclerosis drug Gilenya ( fingolimod ).

The U.S. Food and Drug Administration is alerting health care professionals and patients about injuries and death associated with the use of an experimental procedure sometimes called “liberation therapy” or the “liberation procedure” to treat chronic cerebrospinal venous insufficiency ( CCSVI ).

The U.S. Food and Drug Administration (FDA) is informing the public of an increased risk of second primary malignancies (new types of cancer) in patients with newly-diagnosed multiple myeloma who received Revlimid ( lenalidomide ).

The U.S. Food and Drug Administration approved Elelyso ( taliglucerase alfa ) for long-term enzyme replacement therapy to treat a form of Gaucher disease, a rare genetic disorder.

The U.S. Food and Drug Administration issued warning letters to ten manufacturers and distributors of dietary supplements containing  dimethylamylamine , more popularly known as DMAA , for marketing products for which evidence of the safety of the product had not been submitted to FDA.

The U.S. Food and Drug Administration (FDA) is notifying the public that co-administration of Victrelis ( boceprevir ), a hepatitis C virus ( HCV ) protease inhibitor, along with certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors, is not recommended at this time. Because of the possibility of reducing the effectiveness of the medicines, permitting the amount of HCV or HIV virus in the blood (viral load) to increase. Ritonavir-boosted HIV protease inhibitors include ritonavir-boosted Reyataz ( atazanavir ), ritonavir-boosted Prezista ( darunavir ), and Kal...